Sulodexide

Summary

Sulodexide (CHEMBL2108086) is a phase-3 clinical-stage unknown (ATC B01AB11); indicated across 9 conditions including thrombotic disease and chronic kidney disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: B01AB11
• Indications: 9 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108086
Name	Sulodexide
Type	Unknown
Max phase	3
ATC	B01AB11

Also known as: Sulodexida, Sulodexide, Vessel due f, SULODEXIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	3	MONDO:0000831	HP:0004419
chronic kidney disease	3	MONDO:0005300	EFO:0003884
diabetic kidney disease	3	MONDO:0005016	EFO:0000401
peripheral arterial disease	3	MONDO:0005386	EFO:0004265
venous thromboembolism	3	MONDO:0005399	EFO:0004286
diabetic retinopathy	2	MONDO:0005266	EFO:0003770
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
membranoproliferative glomerulonephritis	1	MONDO:0002461	MONDO:0019736

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	7
PHASE4	4
PHASE2	2
PHASE2/PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00130312	PHASE4	TERMINATED	Effect of Sulodexide in Overt Diabetic Nephropathy
NCT02512601	PHASE4	TERMINATED	Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide
NCT03504566	PHASE4	WITHDRAWN	Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
NCT05252923	PHASE4	TERMINATED	Endothelial Protection in Convalescent COVID-19 Patients
NCT04257487	PHASE3	RECRUITING	Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
NCT06982196	PHASE3	ENROLLING_BY_INVITATION	Sulodexide in Controlling the Recurrence of Psoriasis
NCT00130208	PHASE3	COMPLETED	Effect of Sulodexide in Early Diabetic Nephropathy
NCT00462202	PHASE3	TERMINATED	Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
NCT01000545	PHASE3	UNKNOWN	The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease
NCT03370705	PHASE3	UNKNOWN	Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone
NCT04483830	PHASE2/PHASE3	COMPLETED	Suloexide in the Treatment of Early Stages of COVID-19
NCT05371925	PHASE3	COMPLETED	Endothelial Protection in Post COVID-19 Patients With Sulodexide
NCT01295775	PHASE2	COMPLETED	Diabetic Retinopathy Sulodexide Study
NCT02737670	PHASE2	COMPLETED	Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus
NCT00583427	PHASE1	WITHDRAWN	Sulodexide Treatment in Patients With Dense Deposit Disease
NCT05654233	Not specified	UNKNOWN	The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).